Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
So if I'm right hypothetically those with 50,000 Innomed shares would be sitting on North of £12k based on a listing price US .29 Cents...
There is a need, due to passage of time to update the Share Purchase Agreement (former Class two members). Those affected will receive an email shortly of changes requested by the regulators.
The Company has now started the process of Stock Exchange review (TSXV). The Company will seek a derogation not to have a regulated Sponsor as the prospectus is a non-offering prospectus (not raising capital at listing). There is no certainty we will be given a derogation and if not, the appointment and review of a sponsor can take up to three months.
Patent Application and ?Approvals?
The Company’s specialist patent attorney, Office Freylinger Luxembourg, has advised that in addition to those patents that have been granted and official patent certificates issued for the “Catheter System for Continuous Irrigation” significant progress has been made., the remaining 21 patent applications based on PCT/US2017/026450 theatre still being assessed and reviewed in the individual countries.
PureFlowCath Prototype Design and Manufacture
Management is pleased to advise that Paragon Medical (www.paragonmedical.com) has made significant progress inr the design, engineering and prototype testing of the continuous flow catheter. Further work has also commenced on packaging and production of a functional prototype.
All work will be performed in accordance with “ISO 1485:2016 – Quality Management Systems – Requirements for regulatory purposes” and “21 CFR Part 820 – Quality System Regulations”.
FDA Approval Strategy and Appointment of FDA Specialist Clark Regulatory Solutions, LLC
Management concluded an agreement with Clark Regulatory Solutions, LLC to assist with the planning and execution of our regulatory strategy to guide us through the FDA regulatory processes in the most expeditious way as we work concurrently with Paragon Medical on the development of a prototype.
www.InnomedTec.com
Billy Williams Disclosure Officer/Director +1 251 786 4695 BWilliams@InnomedTec.com
CORPORATE UPDATE JUNE 15, 2022
InnoMed Tech Ltd is holding Company of medical science companies in the business of creating paradigm shifts in thinking to improve clinical outcomes for medical and surgical patients. The Company’s clinical and business leadership team combines years of experience of corporate, and medical science who along with medical engineers, key advisors, work to solve problems presenting in today’s medical and surgical patient population.
Directors Innomed Tec Ltd. (Parent Co):
Robert L. Rhodes - Australia (CEO)
Terrance A. Larkan - Australia (CFO)
Billy Williams - US
David Toyoda - Canada
Dr Marshall Walker- US
Directors PureFlowCath LLC. (US):
Dr Matthew Mcintyre
Robert L. Rhodes
3 to 2 independent directors
Summary of Operations
InnoMed Tech Ltd. (the “Company”) is ?pleased to provide an update on some of the corporate activities and outcomes since the last update on April 4, 2022.
The Company is now concluding the initial debt finance of Euro €10,000,000 to ensure the Company Tech complies with 12-month working capital requirements for prospectus approval. An initial sum is likely to be drawn down before final prospectus approval.
The debt finance has an option for the note holder to convert to equity at same terms as the equity subscription that would result in dilution of current shareholders. Dilution refers to a shareholder’s percentage ownership decreasing as a result of new shares being issued.
CIC Capital Ltd.’s Stuart J. Bromley, Transaction Advisor to the Company, will be emailing every cash subscriber directly with the transaction disclosure documents and an offer same terms; a statutory requirement of any Canadian Issuer.
Since the initial subscription in April 2020 which ushered in a new board and management team, , significant progress has been made in the independent auditing of 3 full years plus interims, completion of administrative requirements for the public listing process, securitisation of patents/applications, prototype design/manufacture and agreement of the FDA device approval strategy. Based on the work done we believe that it is very likely that by peer pricing, the listed price will, in the medium term, be significantly higher than the subscribed pricing of US 29 cents per share.
The debt finance through Luxembourg Securitisation (www.Securitisation.com) is now being concluded, facilitated by the progress made since April 2020 and the advanced stage for regulatory approval of the prospectus.
The debt finance by Luxembourg Securitisation (www.Securitisation.com) is now being concluded due to the advanced stage of regulatory approval of the prospectus.
TSX Venture Exchange Listing Update
The Company’s latest prospectus is attached to this corporate update, dated June 14, 2022.
There is a need, due to passage of time to update the Share Pu
Great news ,what an absolute prick
pro bromley has been banned
Might I suggest we all turn off our mobile phones and computers and go for a walk in the countryside and listen to the birds and bees and learn how to see the beauty all around us?
Probromley
Shareholders calling over and over is a terrible way to run a business. It does not give all shareholders visibility or the ability to track progress against major milestones. And yes…you can give timelines for progress in the hands of the TSX. Based on hundreds of companies that have been listed it is easy to see typical timelines for listing. Their website show standard timeline BY activity. This is not hard to comprehend. My guess is SB continues to have listing issues due to his prior delisting in Canada and on other exchanges. Either that or he is busy sneaking Faberge artifacts out of Russia with the help of the boy scouts:)
In terms of milestones it should also be easy to provide milestones based on operational activities WITH timelines. CIC lacks any resemblance of professionalism or standard business practices, which would include setting targets. How do you measure success without setting targets and measuring against those targets?
What a nasty piece of work you are ,looking at my posting history and making snide comments.You do not know that Syme is going to take a long time to recover and yes you idiot I know what investments I make and do quiet well .I do not comment on all Chat boards I am invested in which you obviously assume I do.You presume I have not spoke to Stuart much however I have spoke to him may times over the years so crawl back into your hole wherever you came from.I do not as you know from my posting history converse with cretins like you so are filtered.
why do you not ask the questions to Stuart .I have asked on the phone and by email many times and get nowhere.I do not know who you are.Just all of a sudden turning up here .With the name probromley which seems very strange to me.
I also received the same message from Stuart.I emailed him back with this Thanks Stuart for the update which is exciting.Have you any idea when a relist is on the cards which is what all shareholders want.I know that is a difficult question but I had to ask anyway.The reply was
I guess you are asking about CIC Capital Ltd.
CIC Capital has always been a private company who’s shareholders were created from a share dividend from CIC Capital Fund Ltd (former listed entity).
It is unlikely that CIC Capital will list in the near future as it has very significant dealings a many high value client companies.
This value will be reflected in the revenue, share holding and securitisation of those clients. The Board whom I do not control will follow the majority of the shareholders wishes (banks and funds). This notion I have huge say is a fantasy by those trying to push an agenda.
You cannot create the scope and depth of CIC companies with different boards of management of the group being controlled by one person.So I sent another email-
I was not meaning it was your fault in any way as previously discussed.I just wonder how as a shareholder I and other shareholders are going to benefit from this situation.Needless to say i never received a reply.
Thank you for posting Ian/Anthony ;)
---How bizarre to "test" your name. Definitely behaviour I look for in a CEO. As I see there are more "updates" without timelines or expectations to track against. I have a few responses…
Prospectus filing dates are very flexible as significant milestones have are being achieved by management and needs to be included in the prospectus.
---Decoding the statement: Prospectus dates are moving targets that we don’t care about due to self-serving decisions related to the CIC entities that only benefit SB. Why can't progress be made in parallel to a submitted prospectus? The answer: IT CAN.
2. Confirmation that PureFlowCath medical device does not require multi year clinical testing as it is an advancement on approved devices (3 year time saving to market)
----How is this new news? The answer: IT IS NOT. In the 2021, January prospectus there were sections dedicated to information about utilizing a "Breakthrough Device Designation" status. In lieu of that a 510k predicate pathway would be utilized. This "progress" is was identified over a 1.5 years ago?
3. Securitisation parties being finalised. I have attached the parties diagram and you can see CIC is way ahead in its Luxembourg operation vs. any competitors
----Who cares about Luxembourg competitors? What an odd statement to mention. I suppose instead of providing a legitimate timeline the only thing CIC has is an ambiguous comparable.
----I have a comparable, The TSX ventures has an average listing time of 3-6 months according to their official site. This means best case CIC is 5x over average.
CIC Capital Ltd is now regulated Transaction Advisor in EU, US and Canada. The multi jurisdiction foot print has now attracted multinational corporation requiring specialist securitisation and coupled with Transaction advisory using a single provider - CIC rather that engaging different legal, accounting and other advisors focused in a particular jurisdiction.
---CIC cannot be a regulator and advisor or a "regulated advisor". That statement makes absolutely no sense. To be a regulator you have to be appointed such as the Canadian Securities Administrators or the Securities and Exchange Commission. What designation does CIC have as a regulated transaction advisor in those locations? If they are simply an advisor they have to stay within the guidelines set by those regulators.
The devil is in the details….
Thanks Ian,
We are always interested to know whom bloggers are and needed to confirm you were MACNAI. Hence I used Anthony.
We like shareholder activism and not worried what is said unless its a denigration of the obligations directors in the CIC Group.
Kind Regards,
Stuart J. Bromley
Mobile Global +44 (0)731 1400014
www.CICCapital.com
www.Securitisation.com
19-25, Rue des Capucins, L-1313 Luxembourg
linkedin
Email from Stuart
Dear Anthony, (my name is Ian)
Please see attached Innomed Tech Ltd updated prospectus filed today.
Prospectus filing dates are very flexible as significant milestones have are being achieved by management and needs to be included in the prospectus.
These material changes include the following:
1 Advancement of PureFlowCath prototype to near completion
2 Confirmation that PureFlowCath medical device does not require multi year clinical testing as it is an advancement on approved devices (3 year time saving to market)
3 Securitisation parties being finalised. I have attached the parties diagram and you can see CIC is way ahead in its Luxembourg operation vs. any competitors
4 Financial Statements are to 31 March 2022 and do not require updating for nine months. Please note the PureFlowCath medical device IP Financial Statements are separate to what is in the prospectus.
5 All IP has been transferred to CIC Fund Securitisation (refer to extensive list of IP in Prospectus Schedules).
6 No debt with the majority 12 month expenditure prepaid
7 CIC has raised US$ 4.1 million in equity finance since 15 April 2020 (date of CIC take over) delivered to client and reflected in Audited Financial Statements.
8 CIC Fund Securitisation S.A. has delivered first debt finance of Euro 1.1 million with Euro 8.9 m in trust account to be delivered on listing. The initial payment to cover 12 month working capital.
CIC Capital Ltd is now regulated Transaction Advisor in EU, US and Canada. The multi jurisdiction foot print has now attracted multinational corporation requiring specialist securitisation and coupled with Transaction advisory using a single provider - CIC rather that engaging different legal, accounting and other advisors focused in a particular jurisdiction.
Please contact my mobile if you require any further inputs.
Kind Regards,
Stuart J. Bromley
Mobile Global +44 (0)731 1400014
www.CICCapital.com
www.Securitisation.com
19-25, Rue des Capucins, L-1313 Luxembourg
linkedin
It has officially been 885 days since the original innomedtec prospectus was submitted to the TSX ventures. In that time China completed a takeover of Hong Kong, a global pandemic hit and covered the world, The Taliban returned to power, the US capitol was attacked, Myanmar military staged a coup, Russia invaded Ukraine and SB has failed to achieve any meaningful progress or a listing. The comparisons are rather stark. It seems as if it is easier for a government to take over another country than for SB to get a listing on a regulated exchange. He needs to be removed and replaced by a legitimate professional. I am assuming he continues to fail to get a listing due to his soiled reputation and prior shady dealings. I am not sure if he continues to use "audits" as an excuse for postponing or if the exchange has no intention of ever getting a company he touches listed. If this continues to drag along I will personally contact the exchange to validate that these activities are actually taking place….time to audit the audit…
Thank you Rob.
Most web sites normally have a link to their new website..
I see that CIC Securitization web site no longer exists. Does that mean that they got what they wanted as in Innomed Tech?
Have they given up on the securitization thing?
Current Web sites..........
https://www.ciccapital.com/
Sedar page for CIC Capital https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00048115
Nothing new there since March 2020
https://www.innomedtec.com/
Sedar page for Innomed https://sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00048771
http://www.cicgold.com/
http://www.cicangel.com/index.html (CIC Capital Fund Ltd .....which Stuart seems to own )
http://cicveritas.com/
As far as I know CIC Capital Fund no longer exists and our free shares no longer exist.
https://www.linkedin.com/in/robert-rhodes-9294aa24/?midToken=AQGYVWWrnOexxA&midSig=2GMqZ5vvB7EGc1&trk=eml-email_pymk_02-pymk-28-prof%7Ephoto&trkEmail=eml-email_pymk_02-pymk-28-prof%7Ephoto-null-1i0j60%7El213on0h%7E6y-null-neptune%2Fprofile%7Evanity%2Eview
Chief Executive Officer / Executive DirectorChief Executive Officer / Executive Director
InnoMed Tech Ltd · Full-timeInnoMed Tech Ltd · Full-time
Mar 2020 - Present · 2 yrs 2 mosMar 2020 - Present · 2 yrs 2 mos
Vancouver, British Columbia, CanadaVancouver, British Columbia, Canada
InnoMed Tech Ltd is the holding company for multiple subsidiary companies working with members of the global medical and scientific community and its team of legal, scientific and financial advisors to develop innovative medical and science products.InnoMed Tech Ltd is the holding company for multiple subsidiary companies working with members of the global medical and scientific community and its team of legal, scientific and financial advisors to develop innovative medical and science products.
What other companies are working with CIC Capital.
They must be more.
This was posted by Sparty1 on ADVFN.
Corporate update received. Regarding listing and patent approval news.. small snippit..
"Summary of Operations
InnoMed Tech Ltd. is?pleased to provide an update on some of the corporate activities and outcomes since the last update on December 16, 2021, and AGM on March 8, 2022.
The Company has begun receiving equity investment inquiries from professional investors and specialist medical technology funds. Any transactions required to be undertaken would be within the strict requirements of the Company’s governance framework, including where necessary, the consultation and approval of existing shareholders.
TSX Venture Exchange Listing Update
The Company’s prospectus review by the regulator remains largely completed, save updating the financial statements. The Company is required to complete, post March 31 2022, audited financial statements to December 31, 2021, and interim financial statement for March 31, 2022 (Q1). On receipt of the audited financial statements for the year ended December 31, 2021 from the Auditor and completion of the interim audited financial statements, the Company will be in a position to then file the updated financial statements in the prospectus for final approval and the listing application on the TSX Venture Exchange. The next review application is expected to be filed before end of April 2022. "
that much ?!?
This is a sick joke. A charade. He’s going through the motions, as they say in sewage treatment circles and what comes out at the end is a processed form of what went in at the beginning.
My prediction is that we end up with a tenth of a penny in the pound.
Preliminary Long Form Prospectus. See for yourself on Innomed web site.
https://www.innomedtec.com/copy-of-about
What’s the prospectus like? Similar with respect to one’s before, I’m not convinced. We all got free shares in several companies that have come to nothing. When will any of the original cic businesses come back
Ian,
Travelling at present.
Your shares in Innomed Tech Ltd is now registered and held electronically. When it gets closer to listing we will then inform you.
Please in the mean time see attched the latest prospectus.
Kind Regards
Stuart J. Bromley